The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Mersana; MSD; Roche; Sotio; Stryker; Zai Lab
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; ImmunoGen; MSD; Roche
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Deutsche Forschungsgemeinschaft (Inst); Deutsche Krebshilfe (Inst); Genmab (Inst); GlaxoSmithKline (Inst); ImmunoGen (Inst); Roche (Inst)
UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer.
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Immunogen; Mersana
Research Funding - Aravive (Inst); Arch Oncology (Inst); ArQule (Inst); AstraZeneca (Inst); Celsion (Inst); Clovis Oncology (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Plexxikon (Inst); Roche (Inst); Shattuck Labs (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
 
Philipp Harter
No Relationships to Disclose
 
David M. O'Malley
Consulting or Advisory Role - Adaptimmune; Agenus; Arcus Biosciences; AstraZeneca; Atossa Therapeutics; BBI Healthcare; Celsion; Clovis Oncology; Corcept Therapeutics; DualityBio; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; InxMed; Jazz Pharmaceuticals; Laekna Therapeutics; Merck; Mersana; Novartis; Novocure; Novocure; OncoC4; Onconova Therapeutics; Regeneron; Roche; Seagen; Sutro Biopharma; Takeda; Toray Industries; Umoja Biopharma; VBL Therapeutics; Verastem; Vincerx Pharma
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Antonio Gonzalez Martin
Consulting or Advisory Role - Alkermes; Amgen; AstraZeneca; Clovis Oncology; Genmab; Hedera Dx; Immunogen; Macrogenics; Mersana; MSD; Novartis; Novocure; Oncoinvent; Pfizer/EMD Serono; Roche; Seagen; SOTIO; Sutro Biopharma; Takeda; Tesaro/GSK
Speakers' Bureau - AstraZeneca; Clovis Oncology; MSD Oncology; PharmaMar; Roche; Tesaro/GSK
Research Funding - Roche (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; PharmaMar; Roche; Tesaro/GSK
 
Thomas J. Herzog
Leadership - GOG Foundation
Consulting or Advisory Role - Aravive; AstraZeneca; Caris MPI; Clovis Oncology; Eisai; Epsilogen; GlaxoSmithKline; Johnson & Johnson; Merck; Mersana; Roche/Genentech; Seagen
 
Caroline Rogalski
Employment - Mersana
Stock and Other Ownership Interests - Mersana
 
Rita Lemming
Employment - Mersana
Stock and Other Ownership Interests - Mersana
 
Erika Keeton
Employment - Mersana
Stock and Other Ownership Interests - Mersana
 
Robert Allen Burger
Employment - Genentech/Roche; Mersana
Stock and Other Ownership Interests - Genentech/Roche; Mersana
Consulting or Advisory Role - Myriad Genetics
 
Mansoor Raza Mirza
Leadership - Karyopharm Therapeutics; Sera Prognostics
Stock and Other Ownership Interests - Karyopharm Therapeutics; Sera Prognostics
Honoraria - Allarity Therapeutics; AstraZeneca; Geneos; Genmab/Seattle Genetics; GlaxoSmithKline; Merck; Mersana; Oncology Venture; Roche; Sotio; Takeda; Zai Lab
Consulting or Advisory Role - AstraZeneca; BioCad; Cerulean Pharma; Genmab; GlaxoSmithKline; Karyopharm Therapeutics; Pfizer; Sotio
Research Funding - Apexigen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Tesaro (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro
Other Relationship - European Network of Gynaecological Oncologic Trials; European Society for Gynaecological Oncology; Gynecological Cancer InterGroup